日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Photoinduced Actin Aggregation Involves Cell Death: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy

光诱导肌动蛋白聚集导致细胞死亡:近红外光免疫疗法后癌细胞毒性的机制

Sato, Kazuhide; Okada, Tomoko; Okada, Ryu; Yasui, Hirotoshi; Yamada, Mizuki; Isobe, Yoshitaka; Nishinaga, Yuko; Shimizu, Misae; Koike, Chiaki; Fukushima, Rika; Takahashi, Kazuomi; Taki, Shunichi; Kato, Ayako; Sato, Mitsuo; Ogura, Toshihiko

Impact of baseline systolic blood pressure on blood pressure changes following renal denervation

基线收缩压对肾脏去神经支配后血压变化的影响

Schmieder, Roland E; Mahfoud, Felix; Mancia, Giuseppe; Townsend, Raymond R; Kandzari, David E; Kario, Kazuomi; Bhatt, Deepak L; Whitbourn, Robert; Liu, Minglei; Böhm, Michael

Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study

不可切除的早期至中期肝细胞癌根治性转化治疗后阿特珠单抗联合贝伐珠单抗停药标准的提议:一项多中心概念验证研究

Aoki, Tomoko; Kudo, Masatoshi; Nishida, Naoshi; Ueshima, Kazuomi; Tsuchiya, Kaoru; Tada, Toshifumi; Morita, Masahiro; Chishina, Hirokazu; Takita, Masahiro; Hagiwara, Satoru; Ida, Hiroshi; Minami, Yasunori; Kuroda, Hidekatsu; Nakamura, Noriaki; Hiraoka, Atsushi; Tomonari, Tetsu; Tani, Joji; Naganuma, Atsushi; Kakizaki, Satoru; Ogawa, Chikara; Hatanaka, Takeshi; Ishikawa, Toru; Kawata, Kazuhito; Takebe, Atsushi; Matsumoto, Ippei; Hidaka, Masaaki; Kurosaki, Masayuki; Kumada, Takashi; Izumi, Namiki

Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT

阿特珠单抗联合贝伐珠单抗治疗不适合经TACE治疗且超出Up-To-7标准的中晚期肝细胞癌:REPLACEMENT研究的最终分析

Ueshima, Kazuomi; Tsuchiya, Kaoru; Yamashita, Tatsuya; Shimose, Shigeo; Numata, Kazushi; Kodama, Yuzo; Itoh, Shinji; Tanaka, Yasuhito; Kuroda, Hidekatsu; Ohkawa, Kazuyoshi; Kuzuya, Teiji; Ikeda, Masafumi; Kooka, Youhei; Aikata, Hiroshi; Hiraoka, Atsushi; Moriguchi, Michihisa; Tateishi, Ryosuke; Ogasawara, Sadahisa; Yamamoto, Kouji; Kudo, Masatoshi

Novel approaches to define responders to interventional treatment in hypertension: insights from the SPYRAL HTN-OFF and HTN-ON MED trials

高血压介入治疗应答者定义的新方法:来自 SPYRAL HTN-OFF 和 HTN-ON MED 试验的启示

Schmieder, Roland E; Hettrick, Douglas A; Böhm, Michael; Kandzari, David E; Kario, Kazuomi; Mahfoud, Felix; Tsioufis, Konstantinos; Weber, Michael A; Esler, Murray D; Townsend, Raymond R

Blood pressure measurement and nocturnal dipping patterns are heavily affected by body posture through changes in hydrostatic pressure between the arm and the heart

血压测量和夜间血压下降模式受身体姿势的显著影响,这是由于手臂和心脏之间的静水压发生变化所致。

Pilz, Niklas; Narkiewicz, Krzysztof; Wolf, Jacek; Kario, Kazuomi; Visser, Tinta; Opatz, Oliver S; Reuter, Alma; Dippel, Laura J; Fesseler, Leon; Heinz, Viktor; Patzak, Andreas; Bothe, Tomas L

Two-year nighttime blood pressure changes after radiofrequency renal denervation: pooled results from the SPYRAL HTN trials

射频肾动脉消融术后两年夜间血压变化:SPYRAL HTN 试验的汇总结果

Kario, Kazuomi; Kandzari, David E; Mahfoud, Felix; Weber, Michael A; Schmieder, Roland E; Tsioufis, Konstantinos; Liu, Minglei; Böhm, Michael; Townsend, Raymond R

Efficacy and safety of esaxerenone in hypertensive patients with chronic kidney disease, with or without type 2 diabetes mellitus: a pooled analysis of five clinical studies

依沙克雷酮治疗伴或不伴2型糖尿病的慢性肾脏病高血压患者的疗效和安全性:五项临床研究的汇总分析

Haruhito A Uchida,Jun Wada,Hirohiko Motoki,Koichiro Kuwahara,Kazuomi Kario,Tomohiro Katsuya,Tatsuo Shimosawa,Kenichi Tsujita,Shoko Suzuki,Tomohiro Suedomi,Takashi Taguchi

Efficacy and safety of esaxerenone with and without sodium-glucose cotransporter-2 inhibitor use in hypertensive patients with type 2 diabetes mellitus: a pooled analysis of five clinical studies

依沙克雷酮联合或不联合钠-葡萄糖协同转运蛋白-2抑制剂治疗2型糖尿病合并高血压患者的疗效和安全性:五项临床研究的汇总分析

Hirohiko Motoki,Koichiro Kuwahara,Haruhito A Uchida,Jun Wada,Kazuomi Kario,Tomohiro Katsuya,Tatsuo Shimosawa,Kenichi Tsujita,Shoko Suzuki,Tomohiro Suedomi,Takashi Taguchi

Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma

IMPACT 研究方案:一项随机、多中心、3 期研究,旨在评估免疫疗法(阿特珠单抗)联合抗 VEGF 疗法(贝伐珠单抗)以及经导管动脉化疗栓塞术治疗不可切除肝细胞癌的疗效。

Kodama, Yoshihisa; Ueshima, Kazuomi; Moriguchi, Michihisa; Inaba, Yoshitaka; Yamashita, Tatsuya; Iwamoto, Hideki; Ueno, Makoto; Ogasawara, Sadahisa; Kuzuya, Teiji; Kodama, Takahiro; Sato, Yozo; Tada, Toshifumi; Tsuchiya, Kaoru; Nishiofuku, Hideyuki; Yamakado, Koichiro; Sone, Miyuki; Ikeda, Masafumi; Takehara, Tetsuo; Hamano, Tetsutaro; Kudo, Masatoshi